Prostate cancer summit

Earlier diagnosis and management of localised prostate cancer was one of the recommended areas of action at the prostate cancer summit.  A link to a newsletter article on PSA testing guidelines for primary care is provided in the updades below.  Thank you to our urology and general practitioner experts who contributed to making the messages clear, practical and consistent with the NHMRC PSA testing guidelines.

All Victorian Primary Health Networks, six in total, are disseminating this article to general practitioners in their catchment via their regular newsletter publications.

Read updates from the summit

Prostate Summit Newsletter - June 2017 - PSA testing guidelines for primary care

Prostate Summit Newsletter - March 2017 - update on progress of prostate summit actions
Prostate Summit Newsletter - October 2016
Prostate Cancer Summit Summary Report 


Watch the prostate cancer summit data presentation


About the Summit

Seventy-one delegates providing care or support to men with prostate cancer attended the summit on Friday 27th May to discuss and identify unwarranted variations in practice and cancer outcomes that could be addressed through state-wide action.

Professor Robert Thomas, Chief Advisor on Cancer (DHHS), opened the event and introduced the Prostate Cancer Optimal Care Pathway (OCP), highlighting the role of collaboration in addressing variations in cancer care for men with prostate cancer. Prof. Damien Bolton, Co-Chair of the Prostate Summit Working Party, set the scene and outlined the purpose of the day. A/Prof Jeremy Millar, Co-Chair of the Prostate Summit Working Party, presented available data on incidence, survival, disease characteristics and treatment planning of men with prostate cancer across Victoria.  View the prostate summit presentation.

A summary of variations in practice and outcomes for Victorian men with prostate cancer was available to participants as a reference.

Prostate cancer care in Victoria presentation highlights:

  • Age-standardised incidence of prostate cancer fell 39% from 2009-2014.  This is highly correlated with the decreasing number of PSA tests
  • Age-standardised mortality of prostate cancer increased from 1982-1994, then fell 2.5% per annum from 1994-2014
  • Lower age-standardised incidence in GRICS and WCMICS, and higher in NEMICS and SMICS.  This is partly explained by the higher incidences at higher Socio-economic Status (SES)
  • Men in regional areas are more likely to present with symptoms, have a TURP for diagnosis, and have metastatic and high-risk disease
  •  In regional areas men are less likely to be recorded as discussed in an MDM, and time from diagnosis to treatment is longer
  •  Prostatectomies are the most common treatment, performed in 42 hospitals, more commonly in metro and private facilities
  • Large variation in modalities of treatment across state even for similar risk disease
  •  Large variation in age-standardised mortality across regions associated with large variation in populations, disease presentation, access to care, and types of care available

Following the data presentation delegates engaged in small group discussions to identify state or local opportunities for action.

Prostate Summit Working Party
A/Prof Jeremy Millar A/Prof Damien Bolton A/Prof Paul Mitchell
A/Prof Declan Murphy A/Prof Justin Tse Prof Ian Davis
A/Prof Sue Evans Dr Keen-Hun Tai Dr David Pook
Mr Mark Frydenberg Mr Paul Kearns Mr Rohan Hall
Mr Nathan Lawrentschuk Dr Mahesh Iddawela Mr Lachlan Dodds

Project team

Ms Mirela Matthews Ms Melinda Williams Mr Luc te Marvelde
Mr Don Vincendese Ms Ella Stuart Ms Megan Dendle

 

print text size increase